PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low density lipoprotein receptor (LDLR) through the LDLR epidermal growth factor-like repeat A (EGF-A) domain and induces receptor internalization and degradation. PCSK9 has emerged as a novel therapeutic target for hypercholesterolemia....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Atherosclerosis 2020-01, Vol.292, p.209-214
Hauptverfasser:	Valenti, Vincenza, Noto, Davide, Giammanco, Antonina, Fayer, Francesca, Spina, Rossella, Altieri, Grazia I., Ingrassia, Valeria, Scrimali, Chiara, Barbagallo, Carlo M., Brucato, Federica, Misiano, Gabriella, Cefalù, Angelo B., Averna, Maurizio R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cells, Cultured Decoy strategy EGF-A domain Epidermal Growth Factor - pharmacology Humans LDLR Mutation PCSK9 PCSK9 inhibition Proprotein Convertase 9 - antagonists & inhibitors Proprotein Convertase 9 - genetics Proprotein Convertase 9 - physiology Receptors, LDL - metabolism Small peptides
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!